- Dec 23, 2012
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
NCT01572480: Phase 2: Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma KRd Multiple myeloma is a blood cancer...
182
- Dec 21, 2012
NCT01754402: Phase 1 / 2 - Bendamustine + Pomalidomide + Dex in Relapsed Multiple Myeloma
This study is designed as a phase I-II, open label, dose finding study. Study treatment will be as follows, in 28 day cycles: ...
244
- Dec 21, 2012
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With RRMM
NCT01665794: Phase 1/2: Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma...
159
- Dec 20, 2012
NCT01677858: Phase 1/2: Weekly Carfilzomib + Dex for Progressive Multiple Myeloma (CHAMPION 1)
CHAMPION Kd A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma (CHAMPION 1) The study had...
217
- Dec 14, 2012
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
NCT01723020: A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma A Phase 1 Study Evaluating AMG 232 in...
83
- Dec 13, 2012
NCT01729091: Phase 2: Umbilical Cord Blood-Derived NK Cells, Elotuzumab, Len, Melphalan f/b ASCT
NCT01729091: Phase 2: Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by...
182